Splenectomy in advanced chronic lymphocytic leukemia.

Area of Science:

• Hematology
• Oncology
• Surgical Oncology

Background:

• Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are lymphoid malignancies.
• Hypersplenism, characterized by anemia and/or thrombocytopenia, and symptomatic splenomegaly are common complications in leukemia patients.
• Splenectomy is a potential treatment option for managing these complications.

Purpose of the Study:

• To evaluate the efficacy of splenectomy in patients with chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL).
• To assess the impact of splenectomy on hematological parameters and survival in these patient populations.

Main Methods:

• Retrospective analysis of 33 patients (30 CLL, 3 PLL) who underwent splenectomy between 1972 and 1989.
• Indications for surgery included hypersplenism (anemia/thrombocytopenia) or symptomatic splenomegaly.
• Evaluation of platelet and hemoglobin increments, duration of response, and survival outcomes post-splenectomy.

Main Results:

• Splenectomy led to significant platelet increments (≥50 x 10(9)/L) in 87% of patients with thrombocytopenia.
• Hemoglobin increments (≥3 gm/dL) were observed in 71% of patients with anemia.
• Median survival from splenectomy was 36 months; median survival from diagnosis was longer for earlier stage disease.

Conclusions:

• Splenectomy is an effective intervention for managing hypersplenism and symptomatic splenomegaly in patients with CLL and PLL.
• The procedure can lead to substantial hematological improvements and potentially prolong survival.
• Further prospective studies in advanced CLL are warranted to confirm these findings.